Always seek the advice of a physician or other qualified healthcare provider with any questions regarding a medical condition
Why this trial matters: First global Phase III success in a disease with no approved targeted therapy Could change management of systemic symptoms and glandular dysfunction Gene Therapy Phase III in Epidermolysis Bullosa Shows Healing Benefit A Phase III gene therapy trial for epidermolysis bullosa (EB) demonstrated significantly better wound healing, less pain, and reduced itching compared with standard care, and the therapy earned FDA approval in 2025 a major advance for this previously untreatable genetic skin disorder
Wegovy is the drug as ozempic just dosed higher and approved by the FDA specifically for weight loss
You can view before and after results from Formation patients to see the standard of care we bring to every treatment
[16] Although cyanocobalamin lacks a defined upper-toxicity threshold due to its water solubility and renal elimination, exceptionally high cumulative doses have been temporally associated with acneiform eruptions, altered potassium homeostasis, and theoretical thrombotic risk, emphasizing the importance of evidence-based dosing
:max_bytes(150000):strip_icc()/GettyImages-1807240274-2c7c39cb23f34a97bb2d8620911c343d.jpg)
